Where partial clinical efficacy is demonstrated availability of standardised assay data will maximise the chances of identification of correlates of protection which can then be used to iteratively improve vaccine efficacy. Where efficacy is absent, confidence in immunological outcome data is equally important to allow developers to make conclusions selleck about whether the vaccine concept has been tested to failure and can thus be confidently terminated. A coordinated multilateral approach to assay harmonization, standardization and identification of central testing centers is underway and will be critical for the development of a highly
effective second generation malaria vaccine. Many in the malaria R&D arena feel that such a vaccine will be necessary if malaria transmission is to be successfully interrupted in high malaria transmission selleck chemicals llc settings. Thus
the drive towards validated assays for immunological outcomes in malaria vaccination may prove vital if malaria is ever to be eradicated globally. The views expressed in this article are those of the authors and do not necessarily represent the views, opinions or stated policy of the World Health Organization. “
“In many parts of the developed world, uptake of measles–mumps–rubella (MMR) vaccine is suboptimal ,  and . The most recent UK data show uptake of the recommended 2 MMR doses by 5 years  stands at 84.8% , in comparison with the WHO target of 95% . In one UK study, failure to immunise with MMR was attributed to conscious parental choice in around 75% of cases , arguably at least in part a legacy of the purported link between MMR and autistic enterocolitis , ,  and . The paper from which the controversy stemmed, published by Dr Andrew Wakefield and colleagues in 1998 , detailed a case series of 12 children presenting within a few days of receiving the MMR vaccine with inflammatory
bowel symptoms and a loss of language and other basic skills. enough That paper, since discredited on methodological and ethical grounds , did not actually provide empirical evidence of a link between MMR and autism, and subsequent studies have shown no association , however substantial and sustained media attention around the purported link  and  was sufficient to create fear and uncertainty in a generation of parents  and . MMR uptake has still not fully recovered – coverage remains lower than it was before the controversy took hold  and  – but it is slowly and steadily increasing . The diseases against which MMR protects are highly contagious and symptoms can be severe: 40% of European measles cases in 2009, and 23% of US measles cases in 2001–2008, were hospitalised  and , and up to 9% of cases experience otitis media, pneumonia or diarrhoea .